Moderna said it is targeting regulatory approval for the shot in 2025.Moderna on Tuesday announced that its combination shot for flu and COVID-19 is the first candidate to make it to late-stage trial. The first participant has been dosed in the trial, which is expected to enroll about 8,000 people in the Northern Hemisphere, the company said on Tuesday. About half of participants will be ages 65 and older, while the other half will be ages 50 to 64. The shot “has the potential to efficiently reduce the overall burden of acute viral respiratory diseases” by protecting against both COVID-19...